Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
GlobalStar (GSAT) Prices 171.4M Public Offering of Voting Common Stock at $0.35/Share
-
Globalstar, Inc. Announces Pricing of Public Offering of Voting Common Stock
-
Cantor Fitzgerald Starts Galapagos NV (GLPG) at Overweight; Filgotinib Seen as Best in Class JAK
-
GlobalStar (GSAT) Announces Proposed $60M Voting Share Offering
-
Globalstar, Inc. Announces Proposed Public Offering of $60 Million in Shares of Voting Common Stock
-
Freddie Mac Prices $634 Million Multifamily K-Deal, K-F56
-
ASOS Plc. (ASC:LN) (ASOMY) PT Lowered to GBp2,500 at Cantor Fitzgerald
-
Loryser Reaches Agreement with Creditors in Uruguay
-
Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
-
Cantor Fitzgerald Upgrades HealthEquity, Inc (HQY) to Overweight
-
CF Finance Acquisition Corp. Announces Closing of $250 Million Initial Public Offering
-
Centene (CNC) Market Expansion Drives PT To $165 At Cantor Fitzgerald
-
Tivity Health, Inc. (TVTY) PT Raised To $52 At Cantor After Non Deal Roadshow
-
Cantor Fitzgerald Reiterates Overweight on Health Insurance Innovations (HIIQ) Following RSA
-
Wells Fargo Asset Management Announces Changes to Global Dividend Opportunity Fund and Utilities and High Income Fund Portfolio Management Teams
-
Form D/A CANTOR FITZGERALD, L.
-
Biohaven (BHVN) Prices 3.355M Share Offering at $37.25/Sh
-
Marinus Pharma (MRNS) Prices 12M Share Offering at $3.75/Sh
-
CF Finance Acquisition Corp. (CFFAU) Prices 25M Share Unit IPO at $10/Unit
-
Biohaven Announces Pricing of Public Offering of Common Shares
-
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
CF Finance Acquisition Corp. Announces Pricing of $250 Million Initial Public Offering
-
Form SC 13D/A BGC Partners, Inc. Filed by: CANTOR FITZGERALD, L. P.
-
Pre-Open Movers 12/12: (FOMX) (BTAI) (CORT) Higher; (SGYP) (NBIX) (PLAY) Lower (more...)
-
UPDATE: Cantor Fitzgerald Upgrades Corcept Therapeutics (CORT) to Overweight
-
Esquire Financial (ESQ) Promotes Eric S. Bader to COO; Hires Michael Lacapria as CFO
-
Esquire Financial Holdings, Inc. Promotes Eric S. Bader To Chief Operating Officer; Hires Michael Lacapria As Chief Financial Officer
-
Makor Group Announces the Expansion of Its Foreign Exchange Division
-
Tivity Health, Inc. (TVTY) Defended at Cantor, Says 'Sell-off Overdone in Our View'
-
Orchid Island Capital Announces December 2018 Monthly Dividend and November 30, 2018 RMBS Portfolio Characteristics
-
Marinus Pharmaceuticals (MRNS) PT Raised to $25 at Cantor Fitzgerald
-
Mereo BioPharma to Present at The BMO Prescriptions for Success Healthcare Conference on 12 December 2018
-
Mereo BioPharma to Present at The BMO Prescriptions for Success Healthcare Conference on 12 December 2018
-
Global Blood Therapeutics (GBT) Says it Priced $150 Million Common Stock Public Offering
-
Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering
-
Rambler Metals & Mining PLC Announces Convertible Loan Note Financing Close
-
Omnicell (OMCL) PT Raised to $80 at Cantor Fitzgerald
-
Global Blood Therapeutics (GBT) Announces $150M Offering of Common Stock
-
Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
-
Cantor Fitzgerald Downgrades Tesaro (TSRO) to Neutral Following Acquisition Offer
-
McEwen Mining Announces 2019 Timmins Exploration Strategy and Funding
-
McEwen Mining Announces 2019 Timmins Exploration Strategy and Funding
-
Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals
-
Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals
-
Mohr Capital Sells Industrial Building In DFW
-
Cantor Fitzgerald Upgrades Vanda Pharmaceuticals (VNDA) to Overweight
-
Anthem (ANTM) PT Raised to $330 at Cantor Fitzgerald
-
Ocular Therapeutix (OCUL) PT Raised to $24 at Cantor Fitzgerald on DEXTENZA Approval
-
GW Pharma (GWPH) PT Lowered to $193 at Cantor Fitzgerald
-
Cantor Fitzgerald Assumes Aimmune Therapeutics (AIMT) at Overweight


